MTHFD2在非肌层浸润性膀胱癌中的表达及其临床意义

刘新城; 黄海花; 彭友彬; 黎明; 郑俊鸿; 林浩

doi:10.13201/j.issn.1001-1420.2020.12.006

MTHFD2在非肌层浸润性膀胱癌中的表达及其临床意义

- 1. 汕头大学医学院第二附属医院泌尿外科(广东汕头, 515065);
- 2. 汕头大学医学院第二附属医院病理科
基金项目:
广东省医学科学技术研究基金(No:B2018267、A2018053)

广东省自然科学基金项目(No:2018A030307047)

汕头市科技计划项目(No:180709154010294)

详细信息

通讯作者: 林浩,E-mail:linh26@mail2.sysu.edu.cn

中图分类号: R737.14

收稿日期: 2020-03-29

Expression of MTHFD2 and its clinical significance in non-muscle-invasive bladder cancer

- 1. Department of Urology, Second Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, 515065, China;
- 2. Department of Pathology, Second Affiliated Hospital of Shantou University Medical College

More Information

Corresponding author: LIN Hao, E-mail: linh26@mail2.sysu.edu.cn

Received Date: 29 March 2020

摘要

摘要: 目的:了解亚甲基四氢叶酸脱氢酶2(MTHFD2)在非肌层浸润性膀胱癌组织中的表达情况及其与肿瘤病理参数及患者预后的关系。方法:通过挖掘GEPIA数据库,分析MTHFD2 mRNA在膀胱癌组织中的表达情况及其表达水平与患者预后的关系;同时,采用免疫组织化学染色方法检测非肌层浸润性膀胱癌组织中MTHFD2蛋白的表达情况,并采用统计学方法进一步分析其表达水平与肿瘤病理参数及患者预后的关系。结果:MTHFD2 mRNA在膀胱癌组织中的表达水平较癌旁组织明显升高,MTHFD2蛋白在非肌层浸润性膀胱癌中的表达水平亦显著高于非癌组织(P＜0.05);非肌层浸润性膀胱癌组织中MTHFD2蛋白表达水平与肿瘤大小、肿瘤数目、病理分期以及复发等病理参数相关(P＜0.05);MTHFD2高表达的膀胱癌患者术后无瘤生存率更低(P＜0.05)。结论:膀胱癌组织中MTHFD2高表达提示患者预后不良,有可能成为一个全新的预测膀胱癌患者预后的生物标志物。
- 膀胱癌 /
- 亚甲基四氢叶酸脱氢酶2 /
- 人 /
- 表达 /
- 病理参数 /
- 预后
Abstract: Objective: To investigate the expression of MTHFD2 in non-muscle-invasive bladder cancer and analyze its relationship with clinicopathological and prognosis of patients. Method: The expression of MTHFD2 mRNA in bladder cancer tissues and its relationship with prognosis were analyzed by mining GEPIA database. Meanwhile, the expression of MTHFD2 protein in non-muscle-invasive bladder cancer tissues was detected by immunohistochemical staining, and its relationship with pathological parameters of tumor and prognosis of patients were further analyzed by statistical methods. Result: The expression of MTHFD2 mRNA in bladder cancer tissues was significantly higher than that in paracancerous tissues, and the expression level of MTHFD2 protein in non-muscle-invasive bladder cancer tissues was also significantly higher than that in non-cancer tissues(P＜0.05). Besides, the expression level of MTHFD2 protein in non-muscle-invasive bladder cancer tissues was correlated with pathological parameters such as tumor size, number of tumors, pathological stage and recurrence, and negatively related to postoperative tumor-free survival rate of patients(P＜0.05).Conclusion: High expression of MTHFD2 in bladder cancer tissue indicates poor prognosis of patients, which may be a new biomarker for predicting prognosis of patients with bladder cancer.
- bladder cancer /
- methylenetetrahydrofolate dehydrogenase 2 /
- human /
- expression /
- pathological parameters /
- prognosis

HTML全文

参考文献(16)

[1]	Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
[2]	Kaufman DS,Shipley WU,Feldman AS.Bladder cancer[J].Lancet,2009,374(9685):239-249.
[3]	Han J,Wang JZ,Yang X,et al.METTL3 promote tumor proliferation of bladder cancer by accelerating pri-miR221/222 maturation in m6A-dependent manner[J].Mol Cancer,2019,18(1):110.
[4]	Chakraborty A,Dasari S,Long W,et al.Urine protein biomarkers for the detection,surveillance,and treatment response prediction of bladder cancer[J].Am J Cancer Res,2019,9(6):1104-1117.
[5]	陈庭,潘鹏,张艳敏,等.锌指E-盒结合同源异形盒-1在膀胱癌细胞中的表达及对肿瘤细胞侵袭的影响[J].临床泌尿外科杂志,2018,33(2):132-136.
[6]	Ducker GS,Rabinowitz JD.One-Carbon Metabolism in Health and Disease[J].Cell Metab,2017,25(1):27-42.
[7]	Scrimgeour KG,Huennekens FM.Occurrence of a dpn-linked,n5,n10-methylene tetrahydrofolic dehydrogenase in ehrlich ascites tumor cells[J].Biochem Biophys Res Commun,1960,2(3):230-233.
[8]	Nilsson R,Jain M,Madhusudhan N,et al.Metabolic enzyme expression highlights a key role for MTHFD2 and the mitochondrial folate pathway in cancer[J].Nat Commun,2014,5:3128.
[9]	Lin H,Huang B,Wang H,et al.MTHFD2 Overexpression Predicts Poor Prognosis in Renal Cell Carcinoma and is Associated with Cell Proliferation and Vimentin-Modulated Migration and Invasion[J].Cell Physiol Biochem,2018,51(2):991-1000.
[10]	Tang Z,Li C,Kang B,et al.GEPIA:a web server for cancer and normal gene expression profiling and interactive analyses[J].Nucleic Acids Res,2017,45(W1):W98-W102.
[11]	Nazki FH,Sameer AS,Ganaie BA.Folate:metabolism,genes,polymorphisms and the associated diseases[J].Gene,2014,533(1):11-20.
[12]	Liu X,Huang Y,Jiang C,et al.Methylenetetrahydrofolate dehydrogenase 2 overexpression is associated with tumor aggressiveness and poor prognosis in hepatocellular carcinoma[J].Dig Liver Dis,2016,48(8):953-960.
[13]	Lin H,Huang B,Wang H,et al.MTHFD2 Overexpression Predicts Poor Prognosis in Renal Cell Carcinoma and is Associated with Cell Proliferation and Vimentin-Modulated Migration and Invasion[J].Cell Physiol Biochem,2018,51(2):991-1000.
[14]	Andrew AS,Gui J,Sanderson AC,et al.Bladder cancer SNP panel predicts susceptibility and survival[J].Hum Genet,2009,125(5-6):527-539.
[15]	Green NH,Galvan DL,Badal SS,et al.MTHFD2 links RNA methylation to metabolic reprogramming in renal cell carcinoma[J].Oncogene,2019,38(34):6211-6225.
[16]	Mejia NR,MacKenzie RE.NAD-dependent methylenetetrahydrofolate dehydrogenase is expressed by immortal cells[J].J Biol Chem,1985,260(27):14616-14620.